Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ibrutinib

FDA-approved product (capsule, oral), marketed as Ibrutinib, Imbruvica.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Ibrutinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chronic lymphocytic leukemia
  • Macroglobulinemia
  • Mantle cell lymphoma
  • Neoplasm
  • Waldenstrom macroglobulinemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bruton's tyrosine kinase (btk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ibrutinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ibrutinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study

    NCT04230304 · start 2020-11-11

    Registered record
    Registry ID
    NCT04230304
    Conditions
    Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma
    Interventions
    Daratumumab; Ibrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-11-11
    Completion
    2025-02-13
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia +1 more
    InterventionDaratumumab; Ibrutinib
    PhasePhase 2
    Registry statusTerminated

  • Dasatinib In Waldenström Macroglobulinemia

    NCT04115059 · start 2019-11-04

    Registered record
    Registry ID
    NCT04115059
    Conditions
    Waldenstrom Macroglobulinemia; DASATINIB
    Interventions
    Dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2019-11-04
    Completion
    2021-12-31
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWaldenstrom Macroglobulinemia; DASATINIB
    InterventionDasatinib
    PhasePhase 1
    Registry statusTerminated

  • Ibrutinib for Relapsed or Refractory Mantle Cell Lymphoma

    NCT04061850 · start 2019-07-01

    Registered record
    Registry ID
    NCT04061850
    Conditions
    Mantle Cell Lymphoma
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-07-01
    Completion
    2020-08-31
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMantle Cell Lymphoma
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

    NCT03737981 · start 2019-01-31

    Registered record
    Registry ID
    NCT03737981
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    Ibrutinib; Obinutuzumab; Observation Activity; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2019-01-31
    Completion
    2026-12-29
    Enrolment
    465

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionIbrutinib; Obinutuzumab; Observation Activity; Venetoclax
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

    NCT03734016 · start 2018-11-01

    Registered record
    Registry ID
    NCT03734016
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    Zanubrutinib; Ibrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-11-01
    Completion
    2024-02-28
    Enrolment
    652

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionZanubrutinib; Ibrutinib
    PhasePhase 3
    Registry statusCompleted

  • Observational Study of Ibrutinib Use in CLL

    NCT03633045 · start 2018-09-01

    Registered record
    Registry ID
    NCT03633045
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-09-01
    Completion
    2022-04-30
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)

    NCT03474679 · start 2018-05-01

    Registered record
    Registry ID
    NCT03474679
    Conditions
    Graft vs Host Disease
    Interventions
    Ibrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-05-01
    Completion
    2021-11-29
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGraft vs Host Disease
    InterventionIbrutinib
    PhasePhase 3
    Registry statusCompleted

  • Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

    NCT03223610 · start 2018-02-09

    Registered record
    Registry ID
    NCT03223610
    Conditions
    Lymphoma; Non-Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma; Burkitt Lymphoma
    Interventions
    Venetoclax; Ibrutinib; Prednisone; Obinutuzumab; Revlimid (lenalidomide)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2018-02-09
    Completion
    2027-12-01
    Enrolment
    155

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma; Non-Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma; Burkitt Lymphoma
    InterventionVenetoclax; Ibrutinib; Prednisone; Obinutuzumab +1 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

    NCT03310619 · start 2017-12-20

    Registered record
    Registry ID
    NCT03310619
    Conditions
    Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular
    Interventions
    JCAR017; Durvalumab; CC-122; Ibrutinib; CC-220; Relatlimab; Nivolumab; CC-99282
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2017-12-20
    Completion
    2023-02-15
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular
    InterventionJCAR017; Durvalumab; CC-122; Ibrutinib +4 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant

    NCT03267186 · start 2017-09-12

    Registered record
    Registry ID
    NCT03267186
    Conditions
    Acute Biphenotypic Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hematopoietic Cell Transplantation Recipient
    Interventions
    Ibrutinib; Laboratory Biomarker Analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-09-12
    Completion
    2021-04-30
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Biphenotypic Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive +1 more
    InterventionIbrutinib; Laboratory Biomarker Analysis
    PhasePhase 2
    Registry statusCompleted

  • Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)

    NCT02959944 · start 2017-05-11

    Registered record
    Registry ID
    NCT02959944
    Conditions
    Chronic Graft Versus Host Disease
    Interventions
    ibrutinib; Placebo; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-05-11
    Completion
    2021-07-12
    Enrolment
    193

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Graft Versus Host Disease
    Interventionibrutinib; Placebo; Prednisone
    PhasePhase 3
    Registry statusCompleted

  • Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia

    NCT03827603 · start 2017-02-21

    Registered record
    Registry ID
    NCT03827603
    Conditions
    AIHA - Warm Autoimmune Hemolytic Anemia
    Interventions
    Ibrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2017-02-21
    Completion
    2022-03-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAIHA - Warm Autoimmune Hemolytic Anemia
    InterventionIbrutinib
    PhasePhase 2
    Registry statusUnknown

  • A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    NCT02760485 · start 2016-12-29

    Registered record
    Registry ID
    NCT02760485
    Conditions
    Lymphoma
    Interventions
    itacitinib; ibrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2016-12-29
    Completion
    2022-06-06
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventionitacitinib; ibrutinib
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

    NCT02991638 · start 2016-11-01

    Registered record
    Registry ID
    NCT02991638
    Conditions
    Chronic Lymphocytic Leukemia; Indolent B-cell Lymphomas; Chronic Hepatitis B; Lymphoma, Small Lymphocytic; Mantle-Cell Lymphoma; Waldenstrom's Macroglobulinaemia; Follicular Lymphoma
    Interventions
    Ibrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2016-11-01
    Completion
    2021-06
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Indolent B-cell Lymphomas; Chronic Hepatitis B; Lymphoma, Small Lymphocytic +3 more
    InterventionIbrutinib
    PhasePhase 3
    Registry statusUnknown

  • Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

    NCT02443077 · start 2016-10-12

    Registered record
    Registry ID
    NCT02443077
    Conditions
    Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type; Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
    Interventions
    Autologous Bone Marrow Transplantation; Autologous Hematopoietic Stem Cell Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Ibrutinib; Laboratory Biomarker Analysis; Melphalan; Pharmacogenomic Study; Placebo Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2016-10-12
    Completion
    2026-12-23
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type; Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
    InterventionAutologous Bone Marrow Transplantation; Autologous Hematopoietic Stem Cell Transplantation; Carmustine; Cyclophosphamide +7 more
    PhasePhase 3
    Registry statusActive not recruiting